|
Renovo is a biopharmaceutical product company and is a leader in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration.
We aim to be first to market with a scar reduction pharmaceutical drug in the US and Europe to capitalise on this huge, unmet market need. Our pipeline includes one drug in phase 3 clinical development, two drugs in phase 2 clinical development and numerous pre-clinical candidates.
An HTML version of our latest Annual Report is available here.
Revise Clinical Trial The Revise Phase III clinical trial of Juvista in scar revision surgery is currently ongoing in nine European countries and the USA. This trial is now fully recruited in all participating countries. |
